A5070923582- T-cell and Retrovirus Studies
- Vector-Borne Animal Diseases
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Histiocytic Disorders and Treatments
- Epigenetics and DNA Methylation
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Animal Disease Management and Epidemiology
- RNA Interference and Gene Delivery
- Cancer-related gene regulation
- Hematopoietic Stem Cell Transplantation
- Alcoholism and Thiamine Deficiency
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- MicroRNA in disease regulation
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiovascular Function and Risk Factors
- Cytomegalovirus and herpesvirus research
University of Tokyo Hospital
2016-2024
Shiga University of Medical Science Hospital
2021-2024
The University of Tokyo
2014-2024
Tokyo Metropolitan Bokutoh Hospital
2023-2024
Tokyo University of Science
2010-2024
Tokyo Medical University Hospital
2017
Tokyo Medical University
2010-2012
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients relapsed, recurrent, or refractory disease. We evaluated the efficacy safety of valemetostat, a potent enhancer zeste homolog 2 (EZH2) EZH1 inhibitor, in treating relapsed (R/R) ATL. This multicenter phase trial enrolled R/R ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day orally until progressive disease unacceptable...
Epigenomes enable the rectification of disordered cancer gene expression, thereby providing new targets for pharmacological interventions. The clinical utility targeting histone H3 lysine trimethylation (H3K27me3) as an epigenetic hallmark has been demonstrated
High disease burden in myeloablative allogeneic hematopoietic stem cell transplantation is associated with adverse outcomes patients acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Quiescent cells could be induced to enter cycle by granulocyte colony-stimulating factor (G-CSF) administration become more susceptible chemotherapy. We report on the outcome of unrelated cord blood (CBT) using a conditioning regimen 12 Gy total body irradiation, G-CSF-combined high-dose...
Abstract Introduction: Enhancer of zeste homolog 2 (EZH2) and its close homolog, EZH1, catalyze the attachment 3 methyl groups to histone H3 at lysine 27. Altered EZH2 expression is implicated in etiology non‐Hodgkin lymphomas (NHLs). Valemetostat tosylate (DS‐3201b; valemetostat) a novel, potent, selective dual inhibitor EZH1. This article protected by copyright. All rights reserved.
Lineage specification is thought to be largely regulated at the level of transcription, where lineage-specific transcription factors drive specific cell fates. MicroRNAs (miR), vital many functions, act posttranscriptionally decrease expression target mRNAs. MLL-AF4 acute lymphocytic leukemia exhibits both myeloid and B-cell surface markers, suggesting that transformed cells are progenitor cells. Through gain- loss-of-function experiments, we demonstrated microRNA 126 (miR-126) drives...
The Ecotropic viral integration site 1 (Evi1) is a zinc finger transcription factor, which located on chromosome 3q26, over-expression in some acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Elevated Evi1 expression AML associated with unfavorable prognosis. Therefore, one of the strong candidate molecular target therapy for leukemia. MicroRNAs (miRNAs) are small non-coding RNAs, vital to many cell functions that negatively regulate gene by translation or inducing...
Strategies integrating activation of innate and adaptive immunity against cancer are desired. We established a novel platform, Wilms' tumor antigen 1 (WT1)-expressing artificial adjuvant vector cells (aAVC-WT1), linking invariant natural killer T (iNKT)-mediated dendritic cell to immunity. Here, we report the first-in-human application aAVC-WT1 in nine patients with relapsed refractory acute myelogenous leukemia. No dose-limiting toxicities were observed, whereas iNKT and/or NK was observed...
Abstract Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal expansion of CD1a + CD207 myeloid dendritic cells. The features LCH are mainly described in children and remain poorly defined adults; therefore, we conducted nationwide survey to collect clinical data from 148 adult patients with LCH. median age at diagnosis was 46.5 (range: 20–87) years male predominance (60.8%). Among the 86 detailed treatment information, 40 (46.5%) had single system LCH, whereas 46...
Adult T-cell leukemia/lymphoma (ATL) is a poor prognosis hematological malignancy originating from human leukemia virus 1 (HTLV-1)-infected CD4+ T cells. Flow cytometric plots of CADM1 and CD7 in cells are useful for separating HTLV-1-uninfected ATL They indicators clonal evolution HTLV-1-infected disease progression asymptomatic carriers or indolent ATL. However, the impacts on clinical course ATL, especially aggressive remain unclear. We focused N fraction (CD4+ CADM1+ CD7-) reflecting...
Abstract We recently took advantage of the universal expression cell adhesion molecule 1 (CADM1) by CD4 + cells infected with HTLV‐1 and downregulation CD7 that corresponds oncogenic stage HTLV‐1‐infected to develop a flow cytometric system using CADM1 versus plotting cells. risk‐stratified asymptomatic carriers (AC) indolent adult T‐cell leukemia/lymphoma (ATL) cases based on percentage, in which clones are efficiently enriched. AC ATL were initially classified according their percentage....
We investigated whether bone marrow or peripheral blood stem cells from older sibling donors cord unrelated provided a better outcome in allogeneic hematopoietic cell transplantation for relatively patients who were candidates myeloablative conditioning. Clinical outcomes of 97 aged 45 years with hematologic malignancies received (CBT) (n = 66) (BMT) (PBSCT) related 31) compared. The cumulative incidences grades III to IV acute and extensive chronic graft-versus-host diseases similar between...
Vincristine (VCR) is an important drug used in the treatment of acute lymphoblastic leukemia (ALL). VCR-induced neurotoxicity can manifest as peripheral neuropathy, constipation, or paralytic ileus. While there are some case reports describing ileus (VIPI) pediatric ALL, fewer publication on adult ALL patients. Therefore, we retrospectively investigated VIPI during induction therapy protocols for 19 The incidence was 32%. significantly increased patients receiving concomitant itraconazole...
ABO blood group incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord transplantation (CBT) yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after myeloablative conditioning for malignant disease our institute. Major mismatch showed a significantly lower incidence platelet engraftment compared match as...
Immunocompromised patients are more likely to develop severe COVID-19, and exhibit high mortality. It is also hypothesized that chronic infection in these can be a risk factor for developing new variants. We describe patient with prolonged active of COVID-19 who became infected during treatment an anti-CD20 antibody (obinutuzumab) follicular lymphoma. This had persistent RT-PCR positivity live virus isolation nine months despite remdesivir other potential antiviral therapies. The computed...
Lineage switches in acute leukemia occur rarely, and the underlying mechanisms are poorly understood. Herein, we report case of an elderly patient with which started as B-cell lymphoblastic (B-ALL) later changed to B- T-cell mixed phenotype (MPAL) myeloid (AML) during consecutive induction chemotherapy treatments. A 65-year-old woman was initially diagnosed Philadelphia chromosome-negative B-ALL primarily expressing TdT/CD34/HLA-DR; more than 20% blasts were positive for...